Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-24 @ 11:49 PM
NCT ID:
NCT04094051
Eligibility Criteria:
Inclusion Criteria:
* In the retrospective part:
1. Male or female patients above 18 years old
2. Patients underwent CLL treatment after Jan 1st, 2013
3. Patient understand and voluntarily sign an ICF, if applicable.
* In the prospective part:
1. Male or female patients above 18 years old
2. Patients diagnosed with CLL，including treatment- naïve patients or patients who have received ≤3 prior therapies
3. Patients treated with ibrutinib as monotherapy or a part of combination therapy
4. Patient understand and voluntarily sign an ICF.
Exclusion Criteria:
* In the retrospective part:
1. Patients with documented diagnosis of other cancers prior to the diagnosis of CLL
2. Patients enrolled in interventional clinical trials of any drug for CLL treatment
* In the prospective part:
1. Patients with documented diagnosis of other cancers prior to the diagnosis of CLL
2. Patients with contraindication listed in the package insert of ibrutinib
3. Patients enrolled in interventional clinical trials of ibrutinib or any other drug for CLL treatment
4. Patient received Ibrutinib treatment as maintenance therapy.
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04094051
Study Brief:
Protocol Section:
NCT04094051